{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T14:16:00Z","timestamp":1783174560494,"version":"3.54.6"},"reference-count":130,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002784","name":"Canada Excellence Research Chairs","doi-asserted-by":"publisher","award":["950-231335"],"award-info":[{"award-number":["950-231335"]}],"id":[{"id":"10.13039\/501100002784","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002784","name":"Canada Excellence Research Chairs","doi-asserted-by":"publisher","award":["191678"],"award-info":[{"award-number":["191678"]}],"id":[{"id":"10.13039\/501100002784","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.atherosclerosis.2026.120716","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:13:17Z","timestamp":1777461197000},"page":"120716","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The secretory PCSK family in cardiovascular disease and beyond"],"prefix":"10.1016","volume":"417","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6503-9342","authenticated-orcid":false,"given":"Nabil G.","family":"Seidah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2026.120716_bib1","series-title":"The endocrine organs","author":"Sharpey-Schafer","year":"1916"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib2","first-page":"251","article-title":"The internal secretion of the pancreas","volume":"7","author":"Banting","year":"1922","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib3","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1042\/bj0590509","article-title":"The amide groups of insulin","volume":"59","author":"Sanger","year":"1955","journal-title":"Biochem J"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib4","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1126\/science.157.3789.697","article-title":"Insulin biosynthesis: evidence for a precursor","volume":"157","author":"Steiner","year":"1967","journal-title":"Science"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1126\/science.161.3837.165","article-title":"Porcine proinsulin: characterization and amino acid sequence","volume":"161","author":"Chance","year":"1968","journal-title":"Science"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib6","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/2081093b0","article-title":"Isolation and amino-acid sequence of beta-LPH from sheep pituitary glands","volume":"208","author":"Li","year":"1965","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib7","first-page":"1163","article-title":"Isolation, purification, and characterization of gamma-lipotropic hormone from sheep pituitary glands, can","volume":"45","author":"Chretien","year":"1967","journal-title":"J Biochem"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib8","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0006-291X(76)80066-6","article-title":"Isolation of peptides with opiate activity from sheep and human pituitaries: relationship to beta-lipotropin","volume":"72","author":"Chretien","year":"1976","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib9","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1073\/pnas.75.10.4719","article-title":"Biosynthesis of beta-endorphin from beta-lipotropin and a larger molecular weight precursor in rat pars intermedia","volume":"75","author":"Crine","year":"1978","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib10","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/0006-291X(77)90616-7","article-title":"Cretien, the complete sequence of sheep beta-endorphin","volume":"74","author":"Seidah","year":"1977","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib11","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1139\/o79-143","article-title":"From beta-lipotropin to beta-endorphin and 'pro-opio-melanocortin'","volume":"57","author":"Chretien","year":"1979","journal-title":"Can J Biochem"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib12","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1210\/endo-97-4-868","article-title":"Evidence of sequential metabolic cleavage of proglucagon to glucagon in glucagon biosynthesis","volume":"97","author":"Noe","year":"1975","journal-title":"Endocrinology"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib13","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/282260a0","article-title":"Identification and processing of proglucagon in pancreatic islets","volume":"282","author":"Patzelt","year":"1979","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1073\/pnas.79.2.345","article-title":"Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem","volume":"79","author":"Lund","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib15","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev.ph.50.030188.001521","volume":"50","author":"Fricker","year":"1988","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib16","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/pro.5560020401","article-title":"Peptidylglycine alpha-amidating monooxygenase: a multifunctional protein with catalytic, processing, and routing domains","volume":"2","author":"Eipper","year":"1993","journal-title":"Protein Sci"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0006-8993(99)01909-5","article-title":"Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides","volume":"848","author":"Seidah","year":"1999","journal-title":"Brain Res"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/v13071229","article-title":"How do enveloped viruses exploit the secretory Proprotein convertases to regulate infectivity and spread?","volume":"13","author":"Seidah","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib19","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1073\/pnas.96.4.1321","article-title":"Mammalian subtilisin\/kexin isozyme SKI-1: a widely expressed proprotein convertase with a unique cleavage specificity and cellular localization","volume":"96","author":"Seidah","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib20","doi-asserted-by":"crossref","first-page":"11041","DOI":"10.1073\/pnas.96.20.11041","article-title":"A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood","volume":"96","author":"Brown","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib21","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/0092-8674(84)90442-2","article-title":"Isolation of the putative structural gene for the lysine-arginine-cleaving endopeptidase required for processing of yeast prepro-alpha-factor","volume":"37","author":"Julius","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib22","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0006-291X(88)80832-5","article-title":"Yeast KEX2 genes encodes an endopeptidase homologous to subtilisin-like serine proteases","volume":"156","author":"Mizuno","year":"1988","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib23","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrd3699","article-title":"The biology and therapeutic targeting of the proprotein convertases","volume":"11","author":"Seidah","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF00429896","article-title":"Furin is a subtilisin-like proprotein processing enzyme in higher eukaryotes","volume":"14","author":"Van de Ven","year":"1990","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib25","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1089\/dna.1991.10.757","article-title":"Identification of a second human subtilisin-like protease gene in the fes\/fps region of chromosome 15","volume":"10","author":"Kiefer","year":"1991","journal-title":"DNA Cell Biol"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib26","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1073\/pnas.88.9.3564","article-title":"PC1 and PC2 are proprotein convertases capable of cleaving proopiomelanocortin at distinct pairs of basic residues","volume":"88","author":"Benjannet","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib27","doi-asserted-by":"crossref","first-page":"8822","DOI":"10.1073\/pnas.89.18.8822","article-title":"Proinsulin processing by the subtilisin-related proprotein convertases furin, PC2, and PC3","volume":"89","author":"Smeekens","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib28","doi-asserted-by":"crossref","first-page":"26488","DOI":"10.1074\/jbc.270.44.26488","article-title":"Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide","volume":"270","author":"Rouill\u00e9","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib29","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0014-5793(97)00892-2","article-title":"Role of the prohormone convertase PC2 in the processing of proglucagon to glucagon","volume":"413","author":"Rouille","year":"1997","journal-title":"FEBS Lett"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib30","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/JOE-18-0596","article-title":"The melanocortin pathway and control of appetite-progress and therapeutic implications","volume":"241","author":"Baldini","year":"2019","journal-title":"J Endocrinol"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib31","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1152\/physrev.00015.2004","article-title":"Hormonal regulation of food intake","volume":"85","author":"Stanley","year":"2005","journal-title":"Physiol Rev"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib32","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12986-016-0153-3","article-title":"Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review","volume":"13","author":"Bodnaruc","year":"2016","journal-title":"Nutr Metab"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/genes12050710","article-title":"Novel homozygous inactivating mutation in the PCSK1 gene in an infant with congenital malabsorptive diarrhea","volume":"12","author":"Aerts","year":"2021","journal-title":"Genes"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib34","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2337\/db11-0305","article-title":"Heterozygous mutations causing partial prohormone convertase 1 deficiency contribute to human obesity","volume":"61","author":"Creemers","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib35","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/ng0797-303","article-title":"Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene","volume":"16","author":"Jackson","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib36","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0300-9084(94)90147-3","article-title":"The family of subtilisin\/kexin like pro-protein and pro-hormone convertases: divergent or shared functions","volume":"76","author":"Seidah","year":"1994","journal-title":"Biochimie"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib37","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/10985549.2024.2348711","article-title":"SPRING is a dedicated licensing factor for SREBP-Specific activation by S1P","volume":"44","author":"Hendrix","year":"2024","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib38","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1210\/endrev\/bnab035","article-title":"The multifaceted biology of PCSK9","volume":"43","author":"Seidah","year":"2022","journal-title":"Endocr Rev"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib39","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1210\/endrev\/bnae031","article-title":"The biology and clinical implications of PCSK7","volume":"46","author":"Sachan","year":"2025","journal-title":"Endocr Rev"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011364","article-title":"Blockade of colon cancer metastasis via single and double silencing of PCSK7\/PCSK9: enhanced T cells cytotoxicity in mouse and human","volume":"13","author":"Porcheron","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib41","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/pro.5560060301","article-title":"Subtilases: the superfamily of subtilisin-like serine proteases","volume":"6","author":"Siezen","year":"1997","journal-title":"Protein Sci"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib42","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100130","article-title":"The PCSK9 discovery, an inactive protease with varied functions in hypercholesterolemia, viral infections, and cancer","volume":"62","author":"Seidah","year":"2021","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072113","article-title":"PCSK9 prosegment chimera as novel inhibitors of LDLR degradation","volume":"8","author":"Luna Saavedra","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib45","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.22354","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration","volume":"48","author":"Zaid","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib46","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib47","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00439-003-1071-9","article-title":"A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree","volume":"114","author":"Timms","year":"2004","journal-title":"Hum Genet"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib48","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.0009-9163.2004.0238.x","article-title":"Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia","volume":"65","author":"Leren","year":"2004","journal-title":"Clin Genet"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib49","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1073\/pnas.0402133101","article-title":"Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype","volume":"101","author":"Maxwell","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib50","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1073\/pnas.0409736102","article-title":"Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment","volume":"102","author":"Maxwell","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib51","doi-asserted-by":"crossref","first-page":"48865","DOI":"10.1074\/jbc.M409699200","article-title":"NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol","volume":"279","author":"Benjannet","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib52","doi-asserted-by":"crossref","first-page":"50630","DOI":"10.1074\/jbc.M410077200","article-title":"Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin\/kexin type 9a in mouse liver","volume":"279","author":"Park","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib53","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat Genet"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib54","doi-asserted-by":"crossref","first-page":"20799","DOI":"10.1074\/jbc.C700095200","article-title":"Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells","volume":"282","author":"McNutt","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib55","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1074\/jbc.M708098200","article-title":"The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2","volume":"283","author":"Poirier","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib56","doi-asserted-by":"crossref","first-page":"30561","DOI":"10.1074\/jbc.M606495200","article-title":"The proprotein convertase PCSK9 is inactivated by furin and\/or PC5\/6A: functional consequences of natural mutations and post-translational modifications","volume":"281","author":"Benjannet","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib57","doi-asserted-by":"crossref","first-page":"13607","DOI":"10.1073\/pnas.201524598","article-title":"Decreased lipid synthesis in livers of mice with disrupted Site-1 protease gene","volume":"98","author":"Yang","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib58","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-Cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American college of Cardiology Solution Set Oversight Committee","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib59","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib60","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/8129513","article-title":"Advantages and disadvantages of inclisiran: a small interfering ribonucleic acid molecule targeting PCSK9-A narrative review","volume":"2022","author":"Mer\u0107ep","year":"2022","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib61","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/dom.16091","article-title":"Inclisiran versus alirocumab in improving lipid profile parameters: a systematic review and meta-analysis","volume":"27","author":"Saad Cleto","year":"2025","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2025.101314","article-title":"The discovery of PCSK9 as a pivotal point in the prevention of cardiovascular disease","volume":"24","author":"Razavi","year":"2025","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib63","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s12265-024-10587-7","article-title":"CRISPR-Cas9 targeting PCSK9: a promising therapeutic approach for atherosclerosis","volume":"18","author":"Gu","year":"2025","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib64","article-title":"mRNA-engineered CRISPR-Cas epigenetic editors enable durable and efficient gene silencing in vivo","volume":"7","author":"Xu","year":"2026","journal-title":"Innovation"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib65","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1001\/jamacardio.2024.1659","article-title":"Efficacy and safety of lerodalcibep in patients with or at high risk of cardiovascular disease: a randomized clinical trial","volume":"9","author":"Klug","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib66","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1093\/eurheartj\/ehad596","article-title":"Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial","volume":"44","author":"Raal","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib67","doi-asserted-by":"crossref","first-page":"16659","DOI":"10.1074\/jbc.M116.717736","article-title":"Proprotein convertase Subtilisin\/Kexin type 9 (PCSK9) single domain antibodies are potent inhibitors of low density Lipoprotein receptor degradation","volume":"291","author":"Weider","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib68","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1515\/hsz-2018-0194","article-title":"A single domain antibody against the Cys- and his-rich domain of PCSK9 and evolocumab exhibit different inhibition mechanisms in humanized PCSK9 mice","volume":"399","author":"Essalmani","year":"2018","journal-title":"Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib69","article-title":"Molecular interactions of PCSK9 with an inhibitory nanobody, CAP1 and HLA-C: functional regulation of LDLR levels","volume":"67","author":"Fruchart Gaillard","year":"2022","journal-title":"Mol Metabol"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib70","article-title":"Development and characterization of a camelid derived antibody targeting a linear epitope in the Hinge domain of human PCSK9 protein","volume":"12","author":"Li","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib71","article-title":"Biparatopic anti-PCSK9 antibody enhances the LDL-uptake in HepG2 cells","volume":"14","author":"Li","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib72","first-page":"65","article-title":"PCSK9 vaccines: a promising new strategy for the treatment of hypercholesterolemia?","author":"Chackerian","year":"2024","journal-title":"JLR (J Lipid Res)"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib73","article-title":"VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys","volume":"65","author":"Vroom","year":"2024","journal-title":"JLR (J Lipid Res)"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib74","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.athplu.2024.11.003","article-title":"Emerging oral therapeutic strategies for inhibiting PCSK9","volume":"59","author":"Ferri","year":"2025","journal-title":"Atherosclerosis Plus"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib75","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jama.2025.20620","article-title":"Efficacy and safety of oral PCSK9 inhibitor enlicitide in adults with heterozygous familial hypercholesterolemia: a randomized clinical trial","volume":"335","author":"Ballantyne","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib76","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/j.jacc.2025.03.499","article-title":"An oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: the PURSUIT randomized trial","volume":"85","author":"Koren","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib77","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2001882","article-title":"Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain","volume":"15","author":"Lintner","year":"2017","journal-title":"PLoS Biol"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib78","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41594-019-0236-8","article-title":"Structural basis for selective stalling of human ribosome nascent chain complexes by a drug-like molecule","volume":"26","author":"Li","year":"2019","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib79","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.2174\/13816128113199990313","article-title":"Proprotein Convertase Subtilisin Kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies","volume":"19","author":"Seidah","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib80","first-page":"1","article-title":"Expanding biology of PCSK9: roles in atherosclerosis and beyond","author":"Seidah","year":"2022","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib81","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1172\/JCI137536","article-title":"Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes","volume":"130","author":"Gan","year":"2020","journal-title":"J Clin Investig"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib82","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1038\/s41467-024-46336-2","article-title":"PCSK9 stimulates Syk, PKC\u03b4, and NF-\u03baB, leading to atherosclerosis progression independently of LDL receptor","volume":"15","author":"Shin","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib83","article-title":"Interactions between PCSK9 and NLRP3 inflammasome signaling in atherosclerosis","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib84","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1038\/s41598-018-20425-x","article-title":"PCSK9 induces a pro-inflammatory response in macrophages","volume":"8","author":"Ricci","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib85","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1161\/CIRCRESAHA.124.325629","article-title":"PCSK9 regulates cardiac mitochondrial cholesterol by promoting TSPO degradation","volume":"136","author":"Laudette","year":"2025","journal-title":"Circ Res"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib86","doi-asserted-by":"crossref","unstructured":"Moon, S.H., Ki, H.W., Yoon, N.H., Chung, K.I., Jo, H., et al., PCSK9 inhibition in myeloid cells enhances cardioprotection beyond its LDL cholesterol-lowering effects, medRxiv, 2024:2024.2008.2027.24312680.","DOI":"10.1101\/2024.08.27.24312680"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib87","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41586-020-2911-7","article-title":"Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer","volume":"588","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib88","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s13238-021-00821-2","article-title":"Potentiating CD8(+) T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling","volume":"12","author":"Yuan","year":"2021","journal-title":"Protein Cell"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib89","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1593\/neo.121252","article-title":"Proprotein convertase subtilisin\/kexin type 9 deficiency reduces melanoma metastasis in liver","volume":"14","author":"Sun","year":"2012","journal-title":"Neoplasia"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib90","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13046-022-02584-y","article-title":"PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity","volume":"42","author":"Gu","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib91","article-title":"High levels of serum cholesterol increase the risk of developing vessel co-opting tumors in colorectal cancer liver metastases","author":"Gantz","year":"2025","journal-title":"FEBS J"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib92","doi-asserted-by":"crossref","first-page":"E4041","DOI":"10.1073\/pnas.1720948115","article-title":"Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment","volume":"115","author":"Peranzoni","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib93","article-title":"A versatile immunomodulated nanoCRISPR converter augments the susceptibility and visibility of tumors to the immune system","volume":"122","author":"Li","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib94","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1002\/hep.26297","article-title":"Implication of the Proprotein convertases in iron homeostasis: proprotein convertase 7 sheds human transferrin receptor 1 and Furin activates hepcidin","volume":"57","author":"Guillemot","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib95","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41419-020-02893-0","article-title":"Shedding of cancer susceptibility candidate 4 by the convertases PC7\/furin unravels a novel secretory protein implicated in cancer progression","volume":"11","author":"Duval","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib96","doi-asserted-by":"crossref","first-page":"6164","DOI":"10.3390\/ijms26136164","article-title":"Shedding of GPP130 by PC7 and furin: potential implication in lung cancer progression","volume":"26","author":"Prabhala","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib97","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1111\/febs.15212","article-title":"Proprotein convertase 7 (PCSK7) reduces apoA-V levels","volume":"287","author":"Ashraf","year":"2020","journal-title":"FEBS J"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155736","article-title":"PCSK7: a novel regulator of apolipoprotein B and a potential target against non-alcoholic fatty liver disease","volume":"150","author":"Sachan","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib99","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.116.025253","article-title":"Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans","volume":"135","author":"Reyes-Soffer","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib100","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jacl.2025.12.023","article-title":"Does apolipoprotein B matter in the care of familial hypercholesterolemia?","volume":"20","author":"Sniderman","year":"2026","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib101","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jacl.2025.11.008","article-title":"ApoB\/LDL-C discordance as a predictor of atherosclerotic cardiovascular disease in genetically confirmed heterozygous familial hypercholesterolemia: a hypothesis-generating cohort study","volume":"20","author":"Genedy","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib102","doi-asserted-by":"crossref","first-page":"553","DOI":"10.5483\/BMBRep.2024-0162","article-title":"Targeting proprotein convertase subtilisin\/kexin type 7 in macrophages as a therapeutic strategy to mitigate myocardial infarction-induced inflammation","volume":"57","author":"Moon","year":"2024","journal-title":"BMB Rep"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib103","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0092-8674(00)80213-5","article-title":"The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor","volume":"89","author":"Brown","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib104","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s10142-025-01694-y","article-title":"MBTPS1: a membrane-bound transcription factor protease implicated in the pathogenesis of several skin and skeletal disorders","volume":"25","author":"Huang","year":"2025","journal-title":"Funct Integr Genomics"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib105","doi-asserted-by":"crossref","first-page":"5732","DOI":"10.1038\/s41467-024-50068-8","article-title":"SPRING licenses S1P-mediated cleavage of SREBP2 by displacing an inhibitory pro-domain","volume":"15","author":"Hendrix","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2025.149969","article-title":"The expanding role of Furin in human Disease: a comprehensive review","volume":"981","author":"Li","year":"2026","journal-title":"Gene"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib107","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1074\/jbc.M110.192104","article-title":"In vivo evidence that furin from hepatocytes inactivates PCSK9","volume":"286","author":"Essalmani","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib108","series-title":"Department of Biochemistry, microbiology, and immunology thesis","article-title":"Regulation of LDL-cholesterol by circulating PCSK9 and its natural variants","author":"Renon","year":"2026"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib109","doi-asserted-by":"crossref","first-page":"26410","DOI":"10.1074\/jbc.M113.501304","article-title":"Furin is the primary in vivo convertase of angiopoietin-like 3 and endothelial lipase in hepatocytes","volume":"288","author":"Essalmani","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib110","doi-asserted-by":"crossref","first-page":"14134","DOI":"10.1074\/jbc.RA118.002426","article-title":"Angiopoietin-like 4 promotes the intracellular cleavage of lipoprotein lipase by PCSK3\/furin in adipocytes","volume":"293","author":"Dijk","year":"2018","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib111","doi-asserted-by":"crossref","first-page":"15747","DOI":"10.1074\/jbc.M110.217638","article-title":"Proteolytic processing of angiopoietin-like protein 4 by Proprotein convertases modulates its inhibitory effects on lipoprotein lipase activity","volume":"286","author":"Lei","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib112","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1073\/pnas.0501652102","article-title":"Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9","volume":"102","author":"Rashid","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib113","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib114","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.111.057406","article-title":"Gene inactivation of PCSK9 reduces atherosclerosis in mice","volume":"125","author":"Denis","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib115","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.atherosclerosis.2019.07.015","article-title":"PCSK9 inhibition and inflammation: a narrative review","volume":"288","author":"Ruscica","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib116","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.639727","article-title":"PCSK9 functions in atherosclerosis are not limited to plasmatic LDL-Cholesterol regulation","volume":"8","author":"Luquero","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib117","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.atherosclerosis.2011.08.035","article-title":"The LDLR deficient mouse as a model for aortic calcification and quantification by micro-computed tomography","volume":"219","author":"Awan","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib118","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064145","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)","volume":"8","author":"Canuel","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib119","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.bbadis.2014.05.009","article-title":"Apolipoprotein E receptor-2 deficiency enhances macrophage susceptibility to lipid accumulation and cell death to augment atherosclerotic plaque progression and necrosis","volume":"1842","author":"Waltmann","year":"2014","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib120","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib121","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib122","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2514428","article-title":"Evolocumab in patients without a previous myocardial infarction or stroke","volume":"394","author":"Bohula","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib123","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in Statin-Treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib124","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1024\/0301-1526\/a001202","article-title":"Atherosclerotic plaque stabilization and regression","volume":"55","author":"Poredo\u0161","year":"2026","journal-title":"Vasa"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib125","article-title":"Survival differences between the USA and an urban population from China for all cancer types and 20 individual cancers: a population-based study","volume":"37","author":"Fu","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.jare.2026.04.020","article-title":"PCSK9 promotes prostate cancer via facilitating intratumoral cholesterol accumulation and enhancing immunosuppressive tumor microenvironment","author":"Gu","year":"2026","journal-title":"J Adv Res"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib127","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.trecan.2024.10.002","article-title":"A new enhancer for anti-PD-1\/PD-L1 immunotherapy: PCSK9 inhibition","volume":"11","author":"Sun","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib128","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1186\/s12885-024-12148-2","article-title":"Targeting PCSK9 to upregulate MHC-II on the surface of tumor cells in tumor immunotherapy","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188581","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): a potential multifaceted player in cancer","volume":"1876","author":"Bhattacharya","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.atherosclerosis.2026.120716_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2026.114859","article-title":"PCSK9-mediated degradation of cell-surface LDL receptors impairs human CD8+ T cell effector functions","volume":"29","author":"Markovska","year":"2026","journal-title":"iScience"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026000821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026000821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T13:22:09Z","timestamp":1783171329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915026000821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":130,"alternative-id":["S0021915026000821"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120716","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The secretory PCSK family in cardiovascular disease and beyond","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120716","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120716"}}